⌘K

Login Start Free

Home/Filings/4/0001104659-23-006235

4//SEC Filing

Palczuk Linda 4

Accession 0001104659-23-006235

CIK 0001012477other

View on SEC.gov Company Profile

Filed

Jan 23, 7:00 PM ET

Accepted

Jan 24, 5:00 PM ET

Size

18.6 KB

Accession

0001104659-23-006235

Insider Transaction Report

Form 4

Period: 2023-01-20

AVADEL PHARMACEUTICALS PLCAVDL

Director

Transactions

Gift
Stock Option (Right to Buy)
2023-01-20−42,000→ 0 total
Exercise: $4.79Exp: 2032-08-03→ ADSs (42,000 underlying)
Gift
Stock Option (Right to Buy)
2023-01-20−60,000→ 0 total
Exercise: $2.03Exp: 2029-08-07→ ADSs (60,000 underlying)
Gift
Stock Option (Right to Buy)
2023-01-20−42,000→ 0 total
Exercise: $8.48Exp: 2030-08-07→ ADSs (42,000 underlying)
Gift
Stock Option (Right to Buy)
2023-01-20−42,000→ 0 total
Exercise: $8.07Exp: 2031-08-03→ ADSs (42,000 underlying)

Holdings

Stock Option (Right to Buy)
(indirect: By Trust)
Exercise: $2.03Exp: 2029-08-07→ ADSs (60,000 underlying)
60,000
Stock Option (Right to Buy)
(indirect: By Trust)
Exercise: $8.07Exp: 2031-08-03→ ADSs (42,000 underlying)
42,000
Stock Option (Right to Buy)
(indirect: By Trust)
Exercise: $4.79Exp: 2032-08-03→ ADSs (42,000 underlying)
42,000
Stock Option (Right to Buy)
(indirect: By Trust)
Exercise: $8.48Exp: 2030-08-07→ ADSs (42,000 underlying)
42,000

Footnotes (5)

[F1]These options are fully vested and exercisable as of the date hereof.
[F2]The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
[F3]On January 20, 2023, the Reporting Person transferred an aggregate of 186,000 options to a revocable trust of which the Reporting Person is trustee.
[F4]These options become exercisable as to 14,000 ADSs on each of the first three anniversaries after the 08/07/2020 grant date, subject to the Reporting Person's continued service at each such vesting date.
[F5]These options shall vest in full on the earlier to occur of (a) August 3, 2023 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time.

Documents

1 file

4
tm234325-1_4seq1.xmlPrimary
OWNERSHIP DOCUMENT

Issuer

AVADEL PHARMACEUTICALS PLC

CIK 0001012477

Entity typeother

Related Parties

1

filerCIK 0001717580

Filing Metadata

Form type: 4
Filed: Jan 23, 7:00 PM ET
Accepted: Jan 24, 5:00 PM ET
Size: 18.6 KB

View on SEC.gov